I’ve seen too many broken systems to know when something is wrong.
There’s no need for white papers or panel discussions to understand what’s happening with drug prices in this country.
Costs are excessively high and have remained that way for years without meaningful change.
That’s why President Donald Trump’s focus on Big Pharma matters.
It’s not about political appeal but because it addresses a problem that has been ignored — or avoided — for too long.
The pharmaceutical industry has become skilled at shifting blame. When prices rise, they point to someone else:
Anyone but the companies actually setting those prices.
But let’s be clear: drug manufacturers determine what a product costs when it enters the market.
And these prices have not been moving in the right direction.
The industry’s standard defense is that research and development is expensive.
While developing new treatments isn’t cheap, innovation matters.
However, this argument becomes less compelling when you consider how much money is spent on activities unrelated to innovation.
During typical TV broadcasts or online browsing, viewers see pharmaceutical ads everywhere — billions of dollars in marketing pushing high-cost brand-name drugs into the mainstream. At the same time, these companies spend heavily in Washington to maintain rules favorable to them.
This combination of pricing power, aggressive marketing, and political influence has kept pressure on drug costs for years.
The change now is a willingness to push back.
The Trump administration’s approach is straightforward: if Americans are paying too much, something in the system must give.
That means examining how prices are set, why competition isn’t reducing costs more, and whether incentives align with patients — or just profits.
It also requires recognizing what works and what doesn’t.
For example, pharmacy benefit managers exist to negotiate prices and create leverage against manufacturers. They aren’t perfect but serve a purpose.
We must not weaken them without addressing the root issue — manufacturer pricing — because that could make the problem worse.
The focus should remain here: healthcare policy is complex, but this part isn’t. If starting prices are too high, everything downstream becomes more expensive.
Right now, too many Americans are bearing the consequences.
I’ve seen what happens when leadership takes on entrenched interests.
And there are those who benefit from keeping things as they are.
But that doesn’t mean we shouldn’t take the fight.
For once, Washington isn’t just talking about drug prices — it’s actually looking at the source of the problem. That is a step in the right direction.
If this holds, it might finally bring relief to those who have been paying the price all along.
